BioAtla Investor Presentation Deck
August 2023, 43 slides
  1. BioAtla
  2. Related Decks
  3. Investor Presentation Decks
conditionally active transforming cancer therapy | BioAtla
important notices disclaimers | BioAtla
is a clinical stage company focused on transforming cancer therapy | BioAtla
leadership team | BioAtla
board of directors and advisors | BioAtla
selective and targeted cab technology widens therapeutic window | BioAtla
broad applicability of cab platform across several antibody types | BioAtla
focused pipeline with broad applicability of differentiated cab assets designed to deliver near term value | BioAtla
cab platform | BioAtla
potential market opportunity in sarcoma | BioAtla
encouraging phase results with | BioAtla
undifferentiated pleomorphic sarcoma ups median months | BioAtla
sarcoma update | BioAtla
phase part topline interim analysis results confirm phase signal | BioAtla
continued promising safety and tolerability profile in sarcoma | BioAtla
potential market opportunity in metastatic | BioAtla
encouraging phase results with | BioAtla
phase study design with | BioAtla
phase part initial interim analysis | BioAtla
change from in sum of target lesions | BioAtla
promising safety and tolerability profile continues to emerge in | BioAtla
dosing regimens under evaluation for cab | BioAtla
summary of dosing regimens for phase clinical studies with cab | BioAtla
cab platform | BioAtla
potential market opportunity in metastatic people the ess available treatment | BioAtla
encouraging phase results with | BioAtla
potential market opportunity in metastatic melanoma | BioAtla
phase results in stage refractory melanoma phase phase | BioAtla
potential market opportunity in | BioAtla
phase results with support advancing into phase | BioAtla
phase study design with in refractory patients | BioAtla
dosing regimens under evaluation for cab | BioAtla
summary of dosing regimens for phase clinical studies with cab | BioAtla
naked antibody i platform basket trial | BioAtla
cab | BioAtla
phase trial design for cab naked antibody tome | BioAtla
platform | BioAtla
cab cell engager a | BioAtla
cleared for cab roc | BioAtla
many key milestones and catalysts throughout | BioAtla
is a clinical stage company focused on transforming cancer therapy | BioAtla
appendix | BioAtla
concentration time profiles from different dosing regimens | BioAtla
See More
BioAtla
Investor Presentation Decks
Biotechnology Decks
Healthcare Decks
Explore Topics
Monotherapy
Tumor
Cancer
Recent decks by BioAtla
Investor Presentation
January 2024
Investor Presentation
May 2023
Investor Presentation
November 2022
Investor Presentation
August 2022
See all presentations by BioAtla (8 decks)
Related decks
Alkermes
Results
June 2021
BioNTech
Results
November 2021
CG Oncology
IPO
March 2024
Immatics
Investor Presentation
November 2023
Alkermes
Investor Presentation
October 2023
Fusion Pharmaceuticals
IPO
June 2020
Immatics
Results
October 2022
Chimerix
Investor Presentation
May 2023
Recent decks by BioAtla
See all presentations (8 decks)
Investor Presentation
January 2024
Investor Presentation
May 2023
Investor Presentation
November 2022
Investor Presentation
August 2022
Alkermes
Results
June 2021
BioNTech
Results
November 2021
CG Oncology
IPO
March 2024
Immatics
Investor Presentation
November 2023
Alkermes
Investor Presentation
October 2023
Fusion Pharmaceuticals
IPO
June 2020
Immatics
Results
October 2022
Chimerix
Investor Presentation
May 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io